View Document Preview and Link Document Date: 2014-10-28 21:29:43 Open Document File Size: 1,28 MB Share Result on Facebook
Company Sirtology Pty Ltd. / Sirtex Medical Limited / MSAC Review / AEs / BioRad Laboratories Pty Ltd / Gray Surgical / / Country Australia / United States / / Currency USD / cent / / IndustryTerm clinical algorithms / magnetic resonance imaging / generic product / stainless steel needles / treatment of non-operable liver cancer / microspheres products / decision analytic protocol / planar imaging / high-energy / travel support / hospital services / treatment algorithm / patient / clinical algorithm / identical ancillary devices / radiological services / competitor product / healthcare resources / poppy seed oil / Serum chemical analyses / / MedicalCondition advanced liver cancer / liver metastases arising secondary / secondary liver cancer / neoplasms / chemotherapy refractory disease / secondary cancers / advanced colorectal cancer / chemorefractory primary liver cancer / secondary cancer / non-colorectal liver metastases / both primary liver cancer / non-melanoma skin cancer / metastatic disease / non-operable liver cancer / microscopic disease / melanoma / resectable / nonablatable hepatocellular carcinoma / recurrent colorectal carcinoma / radiation gastritis / Primary Liver Cancer Primary liver cancer / Colorectal liver metastases / breast cancer / radiation pneumonitis / both primary and secondary liver cancer / tumor / Metastatic Liver Cancer / non-resectable / nonablatable colorectal liver metastases / extra-hepatic cancer / cancer / fatal radiation hepatitis / total cancer / hepatocellular carcinoma / hepatocellular liver carcinoma / primary large bowel cancer / metastases / non-resectable hepatic metastases / tumours / common cancers / extrahepatic disease / Primary Liver Cancer / advanced hepatocellular carcinoma / previously untreated metastatic colorectal cancer / colorectal cancer / malignant liver tumours / hepatic metastases / unresectable disease / Metastatic Liver Cancer MLC / pancreatic cancer / sepsis / oesophageal cancer / cancers / liver metastases / common cancer / disease / either primary liver cancer / acute hepatic necrosis / progressive disease / primary hepatic metastases / tumour / metastatic colorectal cancer / liver tumours / chemorefractory disease / liver cancer secondary / pain / liver dominant disease / lung cancer / Medical condition Liver cancer / liver cancer / extrahepatic metastases / cancer secondary / frequently occurring cancer / varicose veins / uterine fibroids / chemorefractory liver metastases / / MedicalTreatment cannulation / surgery / radiation / chemo / radiation therapy / chemotherapy / chemotherapies / photodynamic therapy / catheter / laser treatment / patient isolation / brachytherapy / / Organization World Health Organization / Australian government / Medicare / Cancer Council Australia / Department of Health / Therapeutic Goods Administration / Medical Services Advisory Committee / / Person Ageing / Bruce Gray / / Position trained physician / Physician / General / Referring physician / qualified radiation safety officer / Major / surgeon / Minister / Radiation safety officer / consultant physician / Nuclear medicine physician / specialist / officer / PASC discussion leader / surgeon / oncologist or related discipline / / Product Cisplatin / HANDLING AND INJECTION / technetium / Irinotecan hydrochloride / Y90 / TACE / fluorouracil / / ProvinceOrState Connecticut / New South Wales / / Region South Wales / Eastern Asia / Southern Europe / Western Africa / / Technology radiation / decision analytic protocol / clinical algorithm / magnetic resonance imaging / clinical algorithms / chemotherapy / tomography / radiopharmaceuticals / laser / DIAGNOSTIC IMAGING / treatment algorithm / 1242 Final Decision Analytic Protocol / targeted chemotherapy / / SocialTag 
1242 Final Decision Analytic Protocol (DAP) to guide the assessment of the use of Y90- microspheres in patients with hepatic primary and secondary cancers September 2012 Table of Contents MSAC and PASC 2